Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation

por Nasu, Risa, James, Douglas E., Chigutsa, Emmanuel, Garhyan, Parag, Nagai, Yukiko
Publicado 2023

Optimization of trial duration to predict long‐term HbA1c change with therapy: A pharmacometrics simulation‐based evaluation

por Kunina, Hanna, Al‐Mashat, Alex, Chien, Jenny Y., Garhyan, Parag, Kjellsson, Maria C.
Publicado 2022

Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: I...

por Harris, Cynthia, Forst, Thomas, Heise, Tim, Plum-Mörschel, Leona, Watkins, Elaine, Zhang, Qianyi, Fan, Ludi, Garhyan, Parag, Porksen, Niels
Publicado 2017

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:12...

por Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.
Publicado 2017